
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a leader in the growing regenerative medicine market, with its strong portfolio of innovative products in the advanced wound care and sports medicine categories. While the company's financial performance has faced some turbulence due to changes in reimbursement structures, we believe that Organogenesis is well-positioned for long-term success, with a large and underpenetrated market opportunity. We see potential for competitive share gains, continued growth in the advanced wound care market, and success in clinical development and milestones. With a diverse portfolio and potential for market consolidation, we have a positive outlook for Organogenesis's stock.
Bears say
Organogenesis Holdings is facing multiple challenges, including lower-than-expected growth for its key product PuraPly, potential pricing pressure from Medicare Part B, increased competition from competitors, and potential issues with Medicare Administrative Contractors. Additionally, there is uncertainty regarding the uptake of new products and potential negative outcomes from clinical data. These factors could lead to lower-than-expected revenue and earnings, putting pressure on the company's stock price.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares